Resumen de: US2023145330A1

Disclosed herein are techniques related to glucose estimation without continuous glucose monitoring. In some embodiments, the techniques may involve receiving input data associated with a user. The input data may comprise discrete blood glucose measurement data associated with the user, activity data associated with the user, contextual data associated with the user, or a combination thereof. The techniques may also involve using an estimation model and the input data associated with the user to generate one or more estimated blood glucose values associated with the user.

Resumen de: US2023141293A1

An insulin pump bolus infusion control method. A control module of a pump body controls the pump body to start a bolus infusion control mode after receiving a function starting signal; in the bolus infusion control mode, a bolus key of a control terminal or a bolus key of an insulin pump body sends an infusion dosage signal to the control module by means of one or more operations; if the control module receives a confirmation signal within a predetermined period of time, then the control module controls the pump body to start bolus infusion; and if the control module receives a cancellation signal or does not receive the confirmation signal within a predetermined period of time, then the control module controls the pump body to exit the bolus infusion mode. Using the method enables an insulin pump to execute a more reasonable control when carrying out the bolus infusion, i.e., starting, setting and implementation of the bolus infusion, and enables a simple and quick operation.

Resumen de: WO2022009071A1

The subject of the invention is a device for non-invasive blood glucose concentration measurement, comprising a central control system (4), a scattering module (1) and an electronic control system (2) of the scattering module (1) connected to it. The electronic control system (2) of the scattering module (1) is connected to the central control system (4). The scattering module (1) comprises a detection element (28) and a coherent radiation source (14) connected to the control system of the coherent radiation source (13). The device is characterized in that it further comprises a transmission module (7) and an electronic control system (8) of the transmission module (7) connected to it, connected to the central control system (4). The device further comprises a proximity sensor (12), connected to the central control system (4). The device comprises an optical fiber probe (11) comprising an emitting optical fiber (15) and a measuring optical fiber (18). The emitting optical fiber (15) is connected to a coherent radiation source (14). The measuring optical fiber (18) is connected to a detection element (28). The emitting optical fiber (15) and the measuring optical fiber (18) are parallel to each other within the optical fiber probe (11). The emitting optical fiber (15) and the measuring optical fiber (18) have a numerical aperture larger or equal to 0.5.

Resumen de: US11642082B1

A method and apparatus for extending the life of a continuous glucose monitor adhesive sensor patch on the body. The apparatus includes an adhesive hold-down, an elastic fabric, and adhering attachments such as Velcro. The apparatus can be fitted around a user's body, with the adhesive hold-down positioned over the sensor adhesive. The apparatus then protects the adhesive from peeling away from skin while in the shower, swimming, or other activities that deteriorate the adhesive.

Resumen de: WO2023077027A1

An electrode system for an electrochemical sensor, such as a glucose sensor, is disclosed. The electrode system includes a working electrode, a reference electrode, and a counter electrode. The working electrode comprises two layers of different metals, such as gold and platinum. The gold layer may have a thickness of about 2.5-3.5 µm, and the platinum layer may have a thickness of about 80-120 Å. The working electrode and the reference electrode are provided on one side of a substrate, and the counter electrode is provided on the opposite side of a substrate.

Resumen de: WO2023073072A1

The computerized method for determining a personalized nutritional recommendation for a user makes use of time data of the concentration of metabolites in the user that are obtained by in vivo measurements carried out regularly over time in the interstitial fluid of the user by at least one wearable sensor worn by the user, including for glucose, non-esterified fatty acids, gylcerol and/or ketone bodies, A computerized recommendation module selects a recommendation suitable for the user according to the time data, by applying rules assigning the recommendations from the list of recommendations to time data of the concentration of metabolites.

Resumen de: WO2023075924A1

Glucose monitoring over phases and corresponding phased information display is described. A multi-phase glucose monitoring program that includes at least a first phase and a second phase is initiated. First glucose data of a user is obtained during the first phase of the multi-phase glucose monitoring program. The output of the first glucose data in a glucose monitoring user interface is prevented during the first phase of the multi-phase glucose monitoring program. Second glucose data of the user is then obtained during a second phase of the multi-phase glucose monitoring program. The second glucose data is output, in real-time, in the glucose monitoring user interface during the second phase of the multi-phase glucose monitoring program.

Resumen de: WO2023070713A1

Closed-loop artificial pancreas drug infusion control system (100), including an infusion module (110), configured to deliver drugs; a program module (120), comprising input end (121) and output end (122), and the input end (121) comprising a plurality of electrically connective regions (121a, 121b) for receiving the current blood glucose level, the program module (120) further preseted with an algorithm, and the algorithm is one or more of rMPC algorithm, rPID algorithm or compound artificial pancreas algorithm, after the output end (122) is electrically connected to the infusion module (110), according to the received current blood glucose level, the algorithm calculates the amount of drug required by the user, and the program module (120) controls the infusion module (110) to output the drug according to the calculated amount of drug required by the user; an infusion cannula (130) with conductive areas, the infusion cannula (130) is the drug infusion channel; and a plurality of electrodes for detecting the blood glucose level, the electrode comprising conductive-area electrodes (171) and cannula-wall electrodes (172), the conductive area of the infusion cannula (130) being at least as a conductive-area electrode (171), and one or more cannula-wall electrodes (171) being located on/in the wall of the infusion cannula (130), when the infusion cannula (130) is installed to the working position, the infusion cannula (130) is connected with the infusion module (110), the drug c

Resumen de: WO2023071457A1

A wearable device (100). By means of the wearable device (100), the blood glucose of a person to be subjected to measurement can be measured. During a blood glucose measurement process, according to the wearable device (100), when it can be ensured by means of a deformation assembly on the wearable device (100) that the measurement condition is consistent every time, a blood glucose measurement assembly on the wearable device (100) is then started to generate a radio frequency signal for measuring blood glucose, and finally, a blood glucose measurement result is obtained. Therefore, the measurement condition during each blood glucose measurement is consistent, thereby improving the accuracy of blood glucose measurement, and enabling the blood glucose of a person to be subjected to measurement to be accurately and conveniently measured by using the wearable device (100).

Resumen de: WO2023070252A1

A closed-loop artificial pancreas insulin infusion control system is provided, including: a detection module (100) configured to the current blood glucose level; a program module (101), connected to the detection module (100), preset with one or more of rMPC algorithm, rPID algorithm or compound artificial pancreas algorithm; and an infusion module (102), connected to the program module (101), can perform anti-hypoglycemic drugs and/or hypoglycemic drugs infusion, the program module (101) controls the infusion module (102) to infuse corresponding drugs, according to the corresponding drug infusion instructions, which is calculated by the rMPC algorithm, rPID algorithm or compound artificial pancreas algorithm. The system is preset with one or more of the rMPC algorithm the rPID algorithm or compound artificial pancreas algorithm, which converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space, making full use of the advantages of rPID algorithm and rMPC algorithm to face complex scenarios, so that the artificial pancreas can provide reliable insulin infusion under various conditions, and blood glucose can reach the ideal level at the expected time, realizing precise control for closed-loop artificial pancreas insulin infusion system.

Resumen de: WO2023070253A1

Closed-loop artificial pancreas insulin infusion control system, includes: a detection module (100,200), configured to detect the current blood glucose level continuously, further provided with a detection processing unit (1001,2001), which preset with an algorithm, and the algorithm calculates the current required insulin infusion amount according to the current blood glucose level; and an infusion module (102,202), connected to the detection module (100,200), the detection module (100,200) sends the current required insulin infusion amount to the infusion module (102,202), and the infusion module (102,202) performs insulin infusion according to the current required insulin infusion amount. After the current blood glucose level is detected, the current required insulin infusion amount is directly calculated without sending it to others, which make the infusion result more accurate and reliable.

Resumen de: WO2023070250A1

A closed-loop artificial pancreas insulin infusion personalized control system includes: a detection module (100) configured to detect the current blood glucose level G continuously; a program module (101), preset with an algorithm for calculating insulin infusion instructions, an adaptive unit for adjusting the gain coefficient of the algorithm according to the user's weight BW, and a preset target blood glucose value GB; and an infusion module (102), connected to and controlled by the program module (101), is configured to infuse insulin according to the corresponding infusion instructions calculated by the algorithm. The system can adjust the gain coefficient of the corresponding algorithm according to the user's weight, which is convenient for personalized settings according to the actual situation of the user, and can better meet the real needs of the user and improve user experience.

Resumen de: WO2023070251A1

It discloses a closed-loop artificial pancreas insulin infusion control system, including: a detection module (100) configured to the current blood glucose level; an infusion module (102), provided with an infusion processor (1021), the infusion processor (1021) calculates the first insulin infusion amount I 1 according to the current blood glucose level by a first algorithm; a second processor (1031, 1001), the second processor (1031, 1001) calculates the second insulin infusion amount I 2 according to the current blood glucose level by a second algorithm; and an electronic module (103), the electronic module (103) optimizes the calculation of the first insulin infusion amount I 1 and the second insulin infusion amount I 2 to obtain the final insulin infusion amount I 3 by a third algorithm, and send the final insulin infusion amount I 3 to the infusion module (102), and the infusion module (102) performs insulin infusion according to the final infusion amount I 3. Through further optimization of the first insulin infusion amount I 1 and the second insulin infusion amount I 2, the final infusion result is more accurate and reliable, realizing precise control of the closed-loop artificial pancreatic insulin infusion control system.

Resumen de: WO2023070247A1

A closed-loop artificial pancreas insulin infusion control system, including a detection module (100) configured to the current blood glucose level G; a program module (101), connected to the detection module (100), preset with a compound artificial pancreas algorithm, including a first algorithm and a second algorithm. The first algorithm is used to calculate the first insulin infusion amount I 1, the second algorithm is used to calculate the second insulin infusion amount I 2, and the compound artificial pancreas algorithm further optimises I 1 and I 2 to obtain the final insulin infusion amount I 3; and an infusion module (102), connected to the program module (101), the program module (101) sends the final insulin infusion amount I 3 to the infusion module (102), the infusion module (102) is configured to infuse insulin according to the final insulin infusion amount I 3. Through further optimisation of the first insulin infusion amount I 1 and the second insulin infusion amount I 2, the final infusion result is more accurate and reliable, realising precise control of the closed-loop artificial pancreatic insulin infusion control system.

Resumen de: WO2023070246A1

A closed-loop artificial pancreas insulin infusion control system, including: a detection module (100) configured to detect the current blood glucose level G continuously; a program module (101), preset with an rPID algorithm that converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space and target blood glucose level G B; and an infusion module (102), connected to and controlled by the program module (101), is configured to infuse insulin according to the corresponding output instructions calculated by the rPID algorithm. The simple and robust characteristics of PID algorithm can be retained, and giving the rPID algorithm the advantages of precision and flexibility, realizing precise control for closed-loop artificial pancreas insulin infusion system.

Resumen de: WO2023075089A1

The present invention relates to a smart insulin injection device capable of constant-temperature storage and, in particular, to a smart insulin injection device comprising: a casing; a syringe which is installed inside the casing and has a guide installed at a lower end thereof to be in close contact with skin when insulin is injected; a cartridge which is accommodated inside the syringe in a state in which insulin is stored and has a piston installed on the upper side thereof and a needle surrounded by the guide and provided on the lower side thereof; an insulin injection part for injecting insulin into skin through the needle by pressing the piston of the cartridge; and a Peltier module which maintains the temperature inside the syringe having the cartridge accommodated therein within a set temperature range by supplying cold or warm air to the syringe, and thus there is an effect that insulin can be stored for a long time without deterioration by storing the insulin remaining in the cartridge at a constant temperature after injection of insulin.

Resumen de: WO2023072306A1

A closed-loop artificial pancreatic insulin infusion control system, comprising: a detection module (100) and an infusion module (102). A detection control unit is provided in the detection module (100); an infusion control unit is provided in the infusion module; at least one of the detection module (100) and the infusion module (102) is provided with a calculation control unit (1, 2) for calculating insulin infusion information and/or further processing different insulin infusion information. Therefore, automatic switching between the control units can be achieved according to different conditions in the closed-loop artificial pancreatic insulin infusion control system, the situation that the user experience is affected, or even a safety risk is brought to a user due to the fact that a certain module of a program unit cannot work normally is avoided, moreover, the situation that the system needs to be integrally replaced when part of functions of part of components fails is avoided, and the utilization rate of the components of a closed-loop artificial pancreas is improved.

Resumen de: WO2023071012A1

A fully closed-loop artificial pancreas drug infusion control system includes a program module (101), at least one detection module (100), a hypoglycemic drug infusion module (104) and an anti-hypoglycemic drug infusion module (103). The program module (101) is preset with an algorithm. The detection module (100) detects the blood glucose level, the hypoglycemic drug infusion module (104) performs hypoglycemic drug infusion according to the infusion instruction calculated by the algorithm, and the anti-hypoglycemic drug infusion module (103) performs anti-hypoglycemic drug infusion according to the infusion instruction calculated by the algorithm, realizing full closed-loop control of drug infusion in artificial pancreas system.

Resumen de: WO2023070245A1

A closed-loop artificial pancreas insulin infusion control system, including: a detection module (100) configured to detect the current blood glucose level G continuously; a program module (101), preset with an rMPC algorithm that converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space and target blood glucose level G B, the rMPC algorithm calculates insulin infusion instructions based on blood glucose risk; and an infusion module (102), connected to the program module (101), and is controlled by the program module (101) to infuse insulin according to the corresponding output instructions calculated by the rMPC algorithm. The system is preset with a rMPC algorithm, which converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space, the recent changes of blood glucose and the asymmetry of distribution are taken into account in the rMPC algorithm, giving the rMPC algorithm the advantages of precision and flexibility, realizing precise control for closed-loop artificial pancreas insulin infusion system.

Resumen de: WO2023075465A1

Disclosed are a system and a method for measuring glucose concentration by using photothermal modulation laser speckle imaging, and a recording medium having recorded thereon a computer-readable program for executing the method. The system for measuring glucose concentration comprises a glucose sensing unit, a photothermal light radiation unit, and a glucose concentration calculation unit. The glucose sensing unit has formed, on the base, a plate layer to which a scatter for laser speckle imaging is fixed, the photothermal light radiation unit radiates light having a predetermined absorption wavelength band of a coenzyme in a glucose oxidase and coenzyme dissolved solution located on the plate layer, and the glucose concentration calculation unit calculates the glucose concentration applied to the glucose sensing unit from changes in temperature in the glucose sensing unit.

Resumen de: US2023136127A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Resumen de: US2023134376A1

This invention pertains to a fluorescence lifetime imaging microscopy (FLIM)-based method for the quantitative three-dimensional (3D) imaging of the metabolic status of a lesion, including the acquisition of FLIM data of a least one anaerobic glycolysis marker. This method applies in particular to lesions such as wounds and tumours, and to markers such as the NADH/NAD+ ratio, the NAD(P)H/NAD+ ratio, the NADH/FAD ratio, the NAD(P)H/FAD ratio or the FADH/FAD ratio as a first marker, and their optional combination with a second marker such as pH, oxygen tension, glucose, pyruvate and lactate.

Resumen de: AU2023202235A1

Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.

Resumen de: AU2023202112A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method ofusing a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.

Resumen de: AU2023202024A1

A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbAlc) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (kage) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgiy), a red blood cell generation rate constant (kgen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbAlc level, and (3) the kage. Further, one or more related analyses (e.g., personalized target glucose range, personalized-target average glucose, cHbAlc, and the like) can be estimated and/or adjusted based on the at least one physiological parameter.